Fig. 2: Combining codon 61 mutants defective in GTPase activity results in an intermediate melanoma phenotype.
From: Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
Melanoma-free survival, overall survival, tumor burden, and tumor growth rates for the following treatment cohorts: a TN61K/R, b TN61L/R, c TN61H/R, d TN61P/R, and e TN61Q/R. Tumor burden and growth rate dot plots are presented as mean values +/− SD. The following number biologically independent animals were evaluated per genotype (61K cohort: R/R = 12, K/R = 19, K/K = 19; 61L cohort: R/R = 13, L/R = 17, L/L = 17; 61H cohort: R/R = 16, H/R = 16, H/H = 17; 61P cohort: R/R = 13, P/R = 20, P/P = 16; 61Q cohort: R/R = 18, Q/R = 21, Q/Q = 22). In a–e, the phenotype of TN61R/R mice was compared to TN61X/X and TN61X/R animals. Log-rank (Mantel–Cox) tests were used to compare survival. One-way ANOVA with a Dunnet T3 multiple comparisons test was used to compare tumor burden and growth between each genotype and TN61R/R for that cohort. Adjusted p-values for all comparisons can be found in Supplementary Table 1f. * p < 0.05, ** p < 0.01, ‡ p < 0.0001. Source data are provided as a Source Data file.
